Takeda Names Julie Kim as New Representative Director, President and CEO

At Takeda’s 150th Annual General Meeting of Shareholders in Osaka, Japan, shareholders elected Julie Kim as a new internal member of the Board of Directors. After the meeting, the Board officially appointed her as Representative Director, President, and CEO.

Following the leadership transition, former President and CEO Christophe Weber retired from both the company and its Board of Directors.

Chair of the Board of Directors Meeting, Masami Iijima, commented: “On behalf of Takeda’s Board of Directors, I would like to congratulate Julie Kim on becoming Takeda’s President and CEO. The Board of Directors is confident in Ms. Kim to drive executional excellence as Takeda launches a number of highly anticipated medicines and grows long-term shareholder value. The Board would like to thank Christophe Weber for his 12 years of extraordinary service to Takeda. He delivered global scale and an innovative pipeline, while strengthening Takeda’s reputation globally as a company built on integrity. We wish him all the best in the future.”

President & CEO, Julie Kim, commented: “It is a privilege and honor to lead Takeda and position the company for long-term profitable growth and increased patient impact. I would like to thank Christophe for his leadership over the last 12 years and in particular, his guidance during the transition period. I would also like to thank our shareholders, Mr. Iijima and the Board of Directors, including the six retiring external Directors, for their support. Going forward, I’m excited to partner with the elected Board to continue our important work for patients and other stakeholders. As we enter our next era, we have three major launches planned in the next 12 months and we are continuing to advance our robust pipeline of five additional highly innovative late-stage assets. Our growth roadmap built around our two strategic horizons positions us for a successful future for patients, our talented employees and shareholders.”

Julie Kim has more than 30 years of experience in the global healthcare industry. Throughout her career, she has focused on driving innovation, improving access to important medicines, and creating positive outcomes for patients and communities.

She joined Takeda in 2019 after the company acquired Shire. Since then, she has held several senior leadership positions, including President of the Plasma-Derived Therapies Business Unit and President of the U.S. Business Unit, before being named CEO-elect in 2025.

Takeda is focused on improving people's health and creating a better future. The company develops and delivers treatments for serious diseases in key areas such as gastrointestinal and inflammatory conditions, rare diseases, plasma-derived therapies, cancer, neuroscience, and vaccines.

Working with its partners, Takeda aims to improve patient care and develop new treatment options through its research and development pipeline. Headquartered in Japan, the company operates in around 80 countries and regions and is guided by a strong commitment to patients, employees, and the environment. Its work is built on values that have shaped the company for more than 200 years.

Read Also- VEC Signs Strategic Partnerships to Expand International Exhibitions in Vietnam